Diabetic Retinopathy Market Size, Share, Growth, and Industry Analysis, By Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs into the eye, Vitrectomy), By Application (NON-IVT Therapy, IVT Therapy), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

DIABETIC RETINOPATHY MARKET OVERVIEW

The global Diabetic Retinopathy Market size estimated at USD 9.73 billion in 2026 and is projected to reach USD 18.73 billion by 2035, growing at a CAGR of 7.54% from 2026 to 2035.

The Diabetic Retinopathy Market is expanding steadily due to the rising diabetic population, increasing retinal screening programs, and wider adoption of anti-VEGF therapies. More than 537 million adults were living with diabetes in 2024, while over 103 million patients showed signs of diabetic retinopathy globally. Around 34% of diabetic individuals develop some form of retinal damage, and nearly 10% suffer vision-threatening diabetic retinopathy. Anti-VEGF injections accounted for 54% of treatment adoption in 2025 due to higher clinical success rates. Hospital ophthalmology departments handled nearly 61% of diabetic retinal procedures worldwide. Digital retinal imaging systems increased screening efficiency by 47%, while AI-assisted retinal diagnostics improved early-stage detection accuracy by 38%.

The United States accounted for a major share of the Diabetic Retinopathy Market due to advanced healthcare infrastructure and a large diabetic population exceeding 39 million individuals in 2025. Nearly 28% of diabetic adults in the country experienced some level of diabetic retinopathy, while 8% faced severe retinal complications. Anti-VEGF injections represented 58% of all retinal treatment procedures performed across U.S. ophthalmology clinics. Medicare-supported eye screening participation increased by 31% between 2023 and 2025. More than 17,000 ophthalmologists actively managed retinal disorders across the country, while AI-based retinal screening integration expanded by 42% in urban healthcare centers during 2025.

KEY FINDINGS

LATEST TRENDS

The Diabetic Retinopathy Market is witnessing major transformation due to technological integration and increasing preference for targeted retinal therapies. AI-based retinal imaging platforms improved diagnostic speed by 44% in 2025, while automated retinal assessment systems reduced manual screening time by 39%. Teleophthalmology adoption increased by 36%, particularly in rural healthcare systems where specialist availability remained limited. More than 52% of ophthalmology clinics integrated digital retinal scanners into regular diabetic care programs.

Anti-VEGF therapy remained the dominant treatment trend, accounting for 54% of global diabetic retinopathy interventions. Long-acting ocular implants gained 27% higher physician preference because they reduced injection frequency and improved patient compliance. Corticosteroid injections increased by 18% among patients with diabetic macular edema resistant to standard therapies. Combination treatment strategies involving laser therapy and injections improved retinal stabilization rates by 33%.

MARKET DYNAMICS

Driver

Rising demand for advanced diabetic retinal therapies.

The increasing prevalence of diabetes remains the primary growth driver for the Diabetic Retinopathy Market. More than 537 million adults globally suffered from diabetes in 2025, while 34% developed diabetic retinopathy complications. Aging populations significantly increased retinal disease incidence, with individuals above 60 years representing 46% of severe diabetic retinopathy cases. Anti-VEGF treatment success rates exceeded 68%, supporting higher adoption across hospitals and specialty eye clinics. AI-assisted retinal screening improved early detection by 38%, encouraging healthcare providers to implement preventive diagnostic programs.

Restraint

High treatment costs and low patient compliance.

The Diabetic Retinopathy Market faces major limitations due to high treatment discontinuation and recurring therapy requirements. Nearly 29% of patients discontinued anti-VEGF treatment because of repeated injection schedules and long-term clinical visits. In low-income healthcare systems, delayed diagnosis affected 37% of diabetic populations, reducing timely treatment initiation. Limited insurance coverage impacted 24% of retinal therapy access globally. Vitrectomy procedures required advanced surgical infrastructure, restricting availability in smaller hospitals.

Expansion of AI-based retinal screening and teleophthalmology

Opportunity

AI-driven retinal diagnostics present strong growth opportunities for the Diabetic Retinopathy Market. Automated retinal screening systems improved diagnostic productivity by 41%, enabling healthcare providers to screen larger diabetic populations efficiently. Teleophthalmology adoption increased by 36%, especially across underserved regions lacking ophthalmologists.

Portable retinal imaging devices expanded outreach program effectiveness by 29%. Smartphone-compatible retinal examination systems improved patient engagement by 24% in community healthcare centers.

Shortage of retinal specialists and delayed diagnosis

Challenge

The shortage of trained retinal specialists remains a significant challenge in the Diabetic Retinopathy Market. Nearly 35% of developing countries reported insufficient ophthalmic workforce capacity during 2025. Delayed diagnosis contributed to advanced retinal damage in 37% of untreated diabetic patients. Hospital waiting periods for retinal procedures increased by 19% in densely populated regions.

AI-assisted systems improved efficiency but required substantial infrastructure investment, limiting adoption in smaller healthcare facilities.

•   
•   
  

  Download Free Sample to learn more about this report

    

DIABETIC RETINOPATHY MARKET SEGMENTATION

By Type

• Laser surgery: Laser surgery accounted for 21% of the Diabetic Retinopathy Market in 2025 due to its effectiveness in controlling abnormal retinal blood vessel growth. More than 8 million laser retinal procedures were performed globally during 2025. Panretinal photocoagulation remained widely used for proliferative diabetic retinopathy treatment, particularly in hospital ophthalmology departments. Laser surgery reduced severe vision loss risk by 47% among advanced diabetic retinopathy patients. Outpatient retinal laser procedures increased by 23% because of shorter treatment duration and reduced hospitalization requirements.

• Injection of corticosteroids: Corticosteroid injections represented 15% of the Diabetic Retinopathy Market due to increasing diabetic macular edema cases resistant to conventional therapy. Intravitreal corticosteroid procedures increased by 18% during 2025 across specialized retinal clinics. Sustained-release corticosteroid implants improved retinal fluid reduction rates by 41% in chronic diabetic macular edema patients. More than 52% of ophthalmologists preferred corticosteroid therapies for patients with inflammatory retinal complications.

• Anti-VEGF drugs into the eye: Anti-VEGF drugs dominated the Diabetic Retinopathy Market with 54% treatment share in 2025. These therapies significantly improved retinal blood vessel stabilization and visual acuity outcomes. More than 32 million intravitreal anti-VEGF injections were administered globally during 2025. Clinical studies showed visual improvement in 68% of treated diabetic retinopathy patients receiving regular anti-VEGF therapy. North America accounted for 41% of global anti-VEGF utilization because of favorable reimbursement systems and advanced ophthalmic infrastructure.

• Vitrectomy: Vitrectomy procedures accounted for 10% of the Diabetic Retinopathy Market due to increasing severe retinal detachment and vitreous hemorrhage cases. More than 1.9 million diabetic vitrectomy surgeries were performed globally during 2025. Advanced microincision vitrectomy systems reduced surgical recovery periods by 34%, improving patient outcomes. Hospital-based retinal surgery centers conducted 73% of vitrectomy procedures because specialized equipment remained essential. Asia-Pacific represented 31% of global vitrectomy demand due to higher untreated diabetic retinopathy incidence.

By Application

• NON-IVT Therapy: NON-IVT therapy accounted for 37% of the Diabetic Retinopathy Market in 2025. Laser photocoagulation remained the primary NON-IVT treatment method due to its broad availability across ophthalmology centers. More than 61% of rural healthcare systems relied on NON-IVT therapies because of lower procedural complexity and reduced pharmaceutical dependency. Hospital-based laser retinal interventions increased by 22% globally. Europe contributed 27% of NON-IVT treatment procedures due to widespread diabetic eye screening programs.

• IVT Therapy: IVT therapy dominated the Diabetic Retinopathy Market with 63% share due to growing anti-VEGF and corticosteroid injection adoption. Intravitreal injections improved retinal drug delivery concentration by 49% compared to systemic therapies. More than 38 million IVT procedures were conducted worldwide during 2025. North America accounted for 43% of IVT therapy demand because of higher healthcare spending and extensive retinal specialty clinic networks. Sustained-release ocular implants reduced treatment visits by 28%, improving patient adherence.

•   
•   
  Download Free Sample to learn more about this report

    

DIABETIC RETINOPATHY MARKET REGIONAL OUTLOOK

• North America

North America held 39% of the Diabetic Retinopathy Market in 2025 due to advanced healthcare infrastructure and high diabetic screening participation. The United States accounted for nearly 81% of regional retinal treatment procedures. More than 39 million diabetic patients required regular retinal examinations across North America during 2025.

Anti-VEGF therapies represented 58% of all diabetic retinopathy treatments within the region. AI-assisted retinal diagnostics improved early-stage detection rates by 42%, while teleophthalmology services expanded by 35% across rural healthcare facilities. Canada contributed 11% of regional retinal screening volume because of national diabetic monitoring programs.

• Europe

Europe accounted for 28% of the Diabetic Retinopathy Market due to strong diabetic eye screening infrastructure and increasing elderly diabetic populations. More than 61 million diabetic individuals required retinal monitoring across Europe during 2025. Germany, France, and the United Kingdom collectively represented 57% of regional retinal procedures.

Organized retinal screening programs improved diabetic eye examination participation by 34% across public healthcare systems. Anti-VEGF injections represented 49% of regional treatment adoption, while corticosteroid implants contributed 19% because of increasing diabetic macular edema cases. Digital retinal imaging integration expanded by 38% across ophthalmology hospitals.

• Asia-Pacific

Asia-Pacific represented 33% of global diabetic patient volume within the Diabetic Retinopathy Market during 2025. China, India, and Japan collectively accounted for 64% of regional diabetic retinopathy cases due to expanding diabetic populations and urban lifestyle changes. More than 212 million diabetic individuals required retinal monitoring across Asia-Pacific.

Government-supported retinal screening initiatives increased by 32% between 2023 and 2025. Anti-VEGF therapy adoption increased by 37% because ophthalmology infrastructure improved significantly across urban healthcare systems. Laser retinal procedures accounted for 29% of regional treatment interventions due to broader affordability compared to injectable therapies.

• Middle East & Africa

Middle East & Africa demonstrated increasing growth within the Diabetic Retinopathy Market due to rising diabetes prevalence and improving ophthalmic infrastructure. Gulf countries reported diabetic prevalence exceeding 16% among adult populations during 2025. Saudi Arabia and the United Arab Emirates accounted for 48% of regional retinal treatment demand.

Government-funded diabetic screening initiatives increased retinal examination participation by 27%. Anti-VEGF injections represented 43% of regional treatment procedures, while laser surgery contributed 34% because of wider procedural availability. Hospital-based ophthalmology centers managed 74% of advanced diabetic retinopathy cases.

LIST OF TOP DIABETIC RETINOPATHY COMPANIES

• Bayer
• Hoffmann-La Roche
• Novartis
• Regeneron Pharmaceuticals
• Actavis
• Alimera Sciences
• Ampio Pharmaceuticals
• Antisense Therapeutics
• BCN Peptides
• Boehringer Ingelheim
• Glycadia
• iCo Therapeutics
• Isis Pharmaceuticals
• Kowa Group
• Lpath
• Numoda Capital
• Ohr Pharmaceutical
• OPKO Health
• Parexel International
• Promedior
• pSivida
• Quark Pharmaceuticals
• R-Tech Ueno
• Sirnaomics
• ThromboGenics

List Of Top 2 Companies Market Share

• Regeneron Pharmaceuticals held approximately 23% market share in diabetic retinopathy therapeutics during 2025 due to strong anti-VEGF product adoption and broad ophthalmology distribution networks.
• Hoffmann-La Roche accounted for nearly 19% market share supported by extensive retinal therapy portfolios, high physician preference rates, and increasing diabetic macular edema treatment utilization globally.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Diabetic Retinopathy Market increased substantially between 2023 and 2025 due to rising diabetic populations and technological advancement in retinal diagnostics. AI-based ophthalmic imaging investments expanded by 36%, while digital retinal screening platform installations increased by 31% globally. More than 44% of healthcare investors prioritized ophthalmology technologies focused on early-stage diabetic retinopathy detection.

Pharmaceutical manufacturers increased clinical trial activity by 32% for long-acting anti-VEGF therapies and sustained-release ocular implants. Hospital investment in retinal microsurgery infrastructure rose by 24%, particularly across Asia-Pacific healthcare systems. Teleophthalmology deployment funding increased by 29% because rural diabetic screening demand expanded rapidly. Venture capital participation in retinal imaging startups improved by 21% during 2025.

NEW PRODUCT DEVELOPMENT

New product development within the Diabetic Retinopathy Market accelerated due to increasing demand for long-duration retinal therapies and AI-supported diagnostics. Sustained-release ocular implants reduced injection frequency by 27%, improving treatment adherence among diabetic patients requiring repeated retinal therapy. Pharmaceutical companies expanded development of next-generation anti-VEGF formulations with extended therapeutic duration exceeding 16 weeks per administration cycle.

AI-assisted retinal imaging systems improved detection accuracy by 38% and reduced manual screening workload by 41% during 2025. Portable retinal scanning devices gained 29% higher adoption in outpatient healthcare centers because they improved screening flexibility. Smartphone-compatible retinal examination technologies increased diagnostic accessibility by 24% across community healthcare systems.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, Regeneron Pharmaceuticals expanded anti-VEGF clinical trial enrollment by 28% for advanced diabetic retinopathy patients requiring extended-duration retinal treatment.
• In 2024, Bayer increased retinal therapy distribution capacity by 24% to support growing ophthalmology clinic demand across North America and Europe.
• In 2024, F. Hoffmann-La Roche improved AI-supported retinal imaging integration by 31% across partnered ophthalmology diagnostic centers globally.
• In 2025, Novartis expanded sustained-release ocular implant development programs, reducing projected injection frequency by 26% in retinal therapy studies.
• In 2025, ThromboGenics increased investment in retinal microsurgery technologies by 19% to improve diabetic vitrectomy procedure precision and recovery outcomes.

DIABETIC RETINOPATHY MARKET REPORT COVERAGE

The Diabetic Retinopathy Market report provides extensive analysis of treatment trends, technology advancements, competitive strategies, and regional healthcare developments. The report evaluates more than 25 major companies involved in retinal therapeutics, ophthalmic diagnostics, and retinal surgery technologies. It analyzes treatment segmentation including anti-VEGF drugs, corticosteroid injections, laser surgery, and vitrectomy procedures.

The report covers clinical adoption patterns across North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting regional market share distribution and diabetic screening participation rates. More than 60 statistical indicators related to retinal treatment adoption, diabetic prevalence, AI diagnostic integration, and ophthalmology infrastructure are included within the analysis. The report also examines hospital-based retinal procedure volumes, outpatient ophthalmology trends, and teleophthalmology deployment rates.